Updates
** Shares of drug developer Sionna Therapeutics SION.O jump as much as 38.9% in their Nasdaq debut; last up 38.1% at $24.86
** Stock opened for trading at $25 vs $18 IPO price, giving it a market capitalization of $1.06 billion
** SION sold ~10.6 million shares, 20% more than initially offered, at the top end of its marketed range of $16 to $18 apiece to raise $190.6 million
** Founded in 2019 and previously known as Sling Therapeutics, SION is developing drugs to treat cystic fibrosis
** SION is vying for a slice of the cystic fibrosis market that is dominated by drugmaker Vertex Pharmaceuticals VRTX.O
** Vertex booked almost $10 billion in sales in 2023 and has significantly impacted cystic fibrosis treatment
** SION is evaluating its experimental drug candidates SION-719 and SION-451 in early-stage trials in Australia
** Prior to the IPO, SION had raised about $330 million from investors, including RA Capital and TPG's Rise Fund
** Goldman Sachs, TD Cowen, Stifel and Guggenheim Securities were the underwriters
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.